La Jolla Institute for Immunology

Statera Biopharma Provides Third Quarter 2021 Financial and Corporate Update

Retrieved on: 
Lundi, novembre 15, 2021
Linda, Corporation, TLR9, TLR4, Cancer, G&A, Consultant, TLR, Infection, TLR8, Cleveland, Immunology, Cleveland BioLabs, Insurance, Severe acute respiratory syndrome coronavirus 2, COVID-19, Research, Entolimod, Crohn's disease, Anemia, Pancreatic cancer, Company, GLOBE, Laboratory, Homeostasis, GAAP, Hope, Pivotal, TLR5, Nasdaq, Patient, Income, Asset, La Jolla Institute for Immunology, Doug Hutchinson, Neutropenia, Animal, Pharmaceutical industry, Financial services, Vaccine, Health insurance, Bank

Statera Biopharma was formerly known as Cleveland BioLabs, Inc. and merged with Cytocom Inc. onJuly 27, 2021.

Key Points: 
  • Statera Biopharma was formerly known as Cleveland BioLabs, Inc. and merged with Cytocom Inc. onJuly 27, 2021.
  • Recent Business and Corporate Highlights:
    Statera Biopharma, Inc. changed its corporate name from Cytocom, Inc. on September 1, 2021, and ticker symbol for common stock was updated from CBLI to STAB.
  • Statera Biopharma, Inc. will host a conference call and live audio webcast on Monday, November 15, 2021, at 5:30 p.m.
  • ET, to discuss its corporate and financial results for the third quarter 2021.

Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2

Retrieved on: 
Mercredi, novembre 10, 2021
National Institute of Allergy and Infectious Diseases, NIAID, Immunity, SAM, Cancer, Foundation for the National Institutes of Health, CORAL, Manuscript, ChAdOx1, RNA transfection, Neoplasm, Coalition, Clinical trial, Immunodeficiency, Infection, Antigen, Security (finance), CEPI, Immune system, HIV, Epidemic, National, Immunization, Coronavirus, Coalition for Epidemic Preparedness Innovations, AZD1222, Severe acute respiratory syndrome coronavirus 2, Mutation, COVID-19, Bill & Melinda Gates Foundation, Forward-looking statement, Program, GMT, National Institute, Epitope, SLATE, Vaccine, U.S. Securities and Exchange Commission, GLOBE, EDGE, Mouse, Vaccination, BioRxiv, Cell, Patient, Head, NIH, AstraZeneca, La Jolla Institute for Immunology, Gilead Sciences, Bill

EMERYVILLE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today published positive preclinical data in non-human primate models from the CORAL next-generation COVID-19 vaccine program against SARS-CoV-2, the coronavirus that causes COVID-19 disease. In a non-human primate challenge study, immunization with a self-amplifying mRNA (SAM) vaccine protected rhesus macaques against SARS-CoV-2 infection as either a homologous prime-boost regimen (2 doses) or as a single boost following an optimized chimpanzee adenoviral (ChAd) vector prime. The manuscript describing these data is available on a preprint server on bioRxiv at https://www.biorxiv.org/content/10.1101/2021.11.08.467773v1 and is concurrently undergoing scientific peer-review for potential publication.

Key Points: 
  • The manuscript describing these data is available on a preprint server on bioRxiv at https://www.biorxiv.org/content/10.1101/2021.11.08.467773v1 and is concurrently undergoing scientific peer-review for potential publication.
  • Advancing new vaccine strategies, like our SAM platform, may help avoid further propagation and mutation of SARS-CoV-2 and potentially address delays in global vaccination.
  • We look forward to sharing preliminary data from our first CORAL trial early in the first quarter of 2022.
  • The self-amplification capability may extend the duration and magnitude of antigen expression, potentially enabling lower vaccine doses or need for frequent repeat administrations.

Lunaphore highlights novel spatial biology research at SITC 2021

Retrieved on: 
Mardi, novembre 9, 2021
Technology, Medical Devices, Hospitals, Science, Biotechnology, Health, Other Science, Research, Other Technology, Aerospace, Manufacturing, Software, Other Health, Hardware, Radiology, Data Management, Oncology, CXCL10, SITC, University, Walter E. Washington Convention Center, COVID-19, La Jolla Institute for Immunology, University of Birmingham, Date, EST, Institute, Society for Immunotherapy of Cancer, Washington Convention Center, Technology, Royal College of Pathologists, Immunology, Society, Multimedia, Research, Neoplasm, Annual general meeting, Solution, CET, Infection, Walter, Mortal Kombat, Pathology, Time, Pharmaceutical industry, Tourism

(Institute of Immunology and Immunotherapy, University of Birmingham)

Key Points: 
  • (Institute of Immunology and Immunotherapy, University of Birmingham)
    Lunaphore will also feature its LabSat and COMET spatial biology solutions at booth #408.
  • Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory.
  • Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity.
  • Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies.

Gritstone Reports Third Quarter 2021 Financial Results and Business Update

Retrieved on: 
Mercredi, novembre 3, 2021
Safety, Gilead, RNA transfection, HIV, CORAL, PIPE, Immunotherapy, NSCLC, Entrepreneurship, Cancer, Vaccine, Coalition for Epidemic Preparedness Innovations, Ipilimumab, Vaccination, Neoplasm, SAM, CEPI, National Institute of Allergy and Infectious Diseases, U.S. Securities and Exchange Commission, Patient, Security (finance), Gilead Sciences, ESMO, Infection, Severe acute respiratory syndrome coronavirus 2, NIAID, Leadership, PD-1, Coalition, Maintenance, Forward-looking statement, Collaboration, Clinical trial, SLATE, Bill & Melinda Gates Foundation, Epidemic, COVID-19, Nivolumab, Cell, National Institute, Research, Immune system, Bill, GLOBE, RECIST, La Jolla Institute for Immunology, Antigen, KRAS, Cryptocurrency, Pharmaceutical industry

We are pleased with our strengthened cash position and the significant clinical progress achieved during this third quarter, said Andrew Allen, M.D., Ph.D., Co-Founder, President and Chief Executive Officer of Gritstone.

Key Points: 
  • We are pleased with our strengthened cash position and the significant clinical progress achieved during this third quarter, said Andrew Allen, M.D., Ph.D., Co-Founder, President and Chief Executive Officer of Gritstone.
  • marketable securities and restricted cash were $216.4 million as of September 30, 2021 compared to $172.1 million as of December 31, 2020.
  • The increase was due to the collaboration revenue associated with the collaboration agreement with Gilead from January 2021.
  • Gritstone undertakes no obligation to update or revise any forward-looking statements.

Gritstone Announces Presentations during Five Upcoming Investor Conferences and Events

Retrieved on: 
Lundi, octobre 25, 2021
CORAL, Cancer, Coalition for Epidemic Preparedness Innovations, NIH, Neoplasm, CEPI, Investor, Gilead Sciences, Gritstone, Infection, Coalition, National, SLATE, Bill & Melinda Gates Foundation, Epidemic, COVID-19, Immunology, Cell, Immune system, Bill, GLOBE, La Jolla Institute for Immunology, Antigen, HIV, Vaccine

EMERYVILLE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will participate in five upcoming investor conferences in October, November and December.

Key Points: 
  • EMERYVILLE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will participate in five upcoming investor conferences in October, November and December.
  • A live webcast of the presentations will be accessible via the Investors & Media section of the companys website at https://ir.gritstonebio.com/investors/events .
  • Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.
  • Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences.

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Vendredi, septembre 24, 2021
Infection, Neoplasm, Coalition for Epidemic Preparedness Innovations, CEPI, Financial compensation, National, Employment, Coalition, Security (finance), Cyprus Securities and Exchange Commission, Cancer, La Jolla Institute for Immunology, CORAL, Board, Immune system, Bill, Immunology, COVID-19, Antigen, Gilead Sciences, NIH, Cell, Bill & Melinda Gates Foundation, HIV, Epidemic, GLOBE, SLATE, Pharmaceutical industry

These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of Gritstones 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.
  • Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.
  • Gritstone undertakes no obligation to update or revise any forward-looking statements.

Twist Bioscience Internally-Discovered Single Domain Antibody TB202-3 Shows Potent Binding to Multiple Strains of SARS-CoV-2, Including Alpha, Beta, and Gamma Strains, in Preclinical Studies

Retrieved on: 
Jeudi, septembre 23, 2021
Technology, Research, Infectious Diseases, Genetics, Nanotechnology, Biotechnology, Health, Pharmaceutical, Science, Blood, NGS, Animal, Weight loss, La Jolla Institute for Immunology, Risk, RNA, Security (finance), Therapy, Top of the Form (quiz show), USAMRIID, Private Securities Litigation Reform Act, DNA, Doctor of Philosophy, Immunoglobulin G, U.S. Securities and Exchange Commission, Patient, Engineering, Infection, Martek Biosciences Corporation, COVID-19, Twist Bioscience, Biology, CEO, N501Y, Human, Genomics, Antibody, Agriculture, Immunology, Technology, Severe acute respiratory syndrome coronavirus 2, VHH, Synthetic biology, RBD, Silicon, Drug discovery, ACE2, United States Army Medical Research Institute of Infectious Diseases, Peplomer, Čović, Time, Urinary tract infection, Mutation, SEC, Vaccine, Pharmaceutical industry, Twist Biopharma Antibodies, The Coronavirus Immunotherapy Consortium (CoVIC), Twist Bioscience Corporation, TWIST BIOPHARMA ANTIBODIES, THE CORONAVIRUS IMMUNOTHERAPY CONSORTIUM (COVIC), TWIST BIOSCIENCE CORPORATION

TB202-3 binds to a specific area (RBD-4) of the SARS-CoV-2 spike protein that has not been impacted by most viral mutations.

Key Points: 
  • TB202-3 binds to a specific area (RBD-4) of the SARS-CoV-2 spike protein that has not been impacted by most viral mutations.
  • This makes it an important and viable candidate for clinical testing in combination with other antibody therapeutics.
  • TB202-3 binds to a majority of known mutations, with the exception of the L452R mutation present in the Delta and Epsilon variants.
  • Target recognition by VHH single domains, on the other hand, requires just a single domain found on heavy chain only antibody.

Gritstone Announces Positive Clinical Data with GRANITE (Individualized Neoantigen Immunotherapy Program) during ESMO 2021 and Launch of Randomized Clinical Trial Program in Colorectal Cancer with Registrational Intent

Retrieved on: 
Vendredi, septembre 17, 2021
Immunotherapy, U.S. Securities and Exchange Commission, Epidemic, Food, Biomarker, Security (finance), Cell, SLATE, Suggestion, Antigen, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CORAL, Bill, National, Immune system, MSS, Patient, CRC, HIV, CEPI, Gilead Sciences, La Jolla Institute for Immunology, Neoplasm, Coalition for Epidemic Preparedness Innovations, RECIST, Immunology, NIH, Disease, Bristol Myers Squibb, Coalition, Infection, GEA, FOLFOX, COVID-19, Bill & Melinda Gates Foundation, Webcast, Gritstone, RNA transfection, TSNA, HLA, Fast Track, Pharmaceutical industry, Vaccine

EMERYVILLE, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced updated results from the Phase 1/2 study evaluating the safety, immunogenicity, and clinical activity of GRANITE individualized neoantigen immunotherapy (heterologous prime-boost in combination with PD-1 checkpoint inhibitor Opdivo® [nivolumab] and subcutaneous anti-CTLA-4 antibody Yervoy® [ipilimumab]) in advanced solid tumors. The data were presented during a mini-oral presentation by investigator and Associate Professor of Medicine at the University of Chicago, Dan Catenacci, MD, as part of the European Society of Medical Oncology (ESMO) Annual Meeting.

Key Points: 
  • These radiological observations were associated with prolonged time on study and decrease in biomarkers such as ctDNA.
  • I am excited to see how well GRANITE can perform in healthier, earlier-stage patients where we expect to see fewer patients progress rapidly before active immunotherapy.
  • Additional information about the trial can be found at www.clinicaltrials.gov, NCT03639714
    Opdivo and Yervoy are trademarks of Bristol-Myers Squibb Company.
  • The companys lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an off-the-shelf shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies.

Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial

Retrieved on: 
Vendredi, septembre 17, 2021
Immunotherapy, U.S. Securities and Exchange Commission, TP53, Epidemic, Security (finance), Ipilimumab, Cell, SLATE, Antigen, Bristol Myers Squibb, CORAL, Bill, National, Immune system, Infection, Patient, CRC, HIV, ESMO, CEPI, Gilead Sciences, La Jolla Institute for Immunology, Neoplasm, Blood, Coalition for Epidemic Preparedness Innovations, RECIST, Immunology, Nivolumab, NIH, Epitope, Coalition, Cancer, Large-cell lung carcinoma, COVID-19, Bill & Melinda Gates Foundation, KRAS, NSCLC, GLOBE, TSNA, PDAC, HLA, RNA transfection, Medical imaging, Vaccine, Pharmaceutical industry

The data from SLATE v1 will be reviewed during the companys previously announced investor event taking place today at 1:30pm ET.

Key Points: 
  • The data from SLATE v1 will be reviewed during the companys previously announced investor event taking place today at 1:30pm ET.
  • SLATE v1 demonstrated the greatest activity in 6 NSCLC patients with the KRASmut G12C presented by the HLA protein A*02:01.
  • SLATE is being evaluated in combination with immune checkpoint blockade in the Phase 2 portion of its clinical study( NCT03953235 ).
  • The companys lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an off-the-shelf shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies.

Gritstone Announces Private Placement Financing of $55.0 Million

Retrieved on: 
Jeudi, septembre 16, 2021
U.S. Securities and Exchange Commission, Security (finance), Epidemic, Cell, SLATE, Antigen, CORAL, Bill, National, Immune system, Infection, HIV, CEPI, Gilead Sciences, La Jolla Institute for Immunology, Securities Act of 1933, Coalition for Epidemic Preparedness Innovations, PIPE, Immunology, NIH, Coalition, Vaccine, Exchange, COVID-19, Bill & Melinda Gates Foundation, Neoplasm, General partnership, GLOBE, RNA transfection, Research, Sale, Cancer, Pharmaceutical industry

Gross proceeds from the PIPE financings total $55.0 million, before deducting placement agent fees and offering expenses.

Key Points: 
  • Gross proceeds from the PIPE financings total $55.0 million, before deducting placement agent fees and offering expenses.
  • This financing will help ensure Gritstone has the resources to move quickly in this exciting new area, and we are excited to support the company in its next phase of growth.
  • The closing of the PIPE financing is subject to customary closing conditions and is expected to close by September 17, 2021.
  • Gritstone bio has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in this private placement.